A discrete choice experiment evaluation of patients’ preferences for different risk, benefit, and delivery attributes of insulin therapy for diabetes management
暂无分享,去创建一个
Scot Simpson | Carlo A Marra | Graydon Meneilly | Larry D Lynd | L. Lynd | C. Marra | G. Meneilly | S. Simpson | S. Gill | Camila Guimarães | Sabrina Gill | Regina HC Queiroz | Camila Guimarães | Regina H C Queiroz
[1] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[2] M. Holiday-Goodman,et al. Identifying factors that affect patients' willingness to pay for inhaled insulin. , 2009, Research in social & administrative pharmacy : RSAP.
[3] Nikos Maniadakis,et al. Patient preference and willingness-to-pay for Humalog Mix25 relative to Humulin 30/70: a multicountry application of a discrete choice experiment. , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[4] W. Cefalu,et al. Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus , 2001, Annals of Internal Medicine.
[5] W. Cefalu. Optimizing Glycemic Control:The Search for Feasible Noninvasive Insulin Delivery Systems , 2003 .
[6] W. Michael Hanemann,et al. Welfare Evaluations in Contingent Valuation Experiments with Discrete Responses , 1984 .
[7] R. Sheldon,et al. Preferences of Patients with Diabetes Mellitus for Inhaled versus Injectable Insulin Regimens , 2012, PharmacoEconomics.
[8] P. Zweifel,et al. Measuring willingness-to-pay for risk reduction: an application of conjoint analysis. , 2002, Health economics.
[9] 2 nd International DAWN Summit : a call-to-action to improve psychosocial care for people with diabetes , 2004 .
[10] John B. Shoven,et al. I , Edinburgh Medical and Surgical Journal.
[11] E. Vermeire,et al. Patient adherence to treatment: three decades of research. A comprehensive review , 2001, Journal of clinical pharmacy and therapeutics.
[12] L. Lynd,et al. A valuation of patients' willingness-to-pay for insulin delivery in diabetes , 2009, International Journal of Technology Assessment in Health Care.
[13] L. Lynd,et al. Reconcilable differences: a cross-sectional study of the relationship between socioeconomic status and the magnitude of short-acting beta-agonist use in asthma. , 2004, Chest.
[14] M. Funnell,et al. MSJAMA: the problem with compliance in diabetes. , 2000, JAMA.
[15] S. Clement,et al. Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2. , 2002, Diabetes technology & therapeutics.
[16] R. Rubin,et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. , 2005, Diabetes care.
[17] S. Francis,et al. Can patients' preferences for involvement in decision-making regarding the use of medicines be predicted? , 2007, Patient education and counseling.
[18] L. Lynd,et al. The impact of low family income on self-reported health outcomes in patients with rheumatoid arthritis within a publicly funded health-care environment. , 2004, Rheumatology.
[19] P. Wilkie,et al. Taking medicines: concordance is not compliance , 1999, BMJ.
[20] Robert M. Anderson,et al. The Problem With Compliance in Diabetes , 2000 .
[21] F. Johnson,et al. Risking health to avoid injections: preferences of Canadians with type 2 diabetes. , 2005, Diabetes care.
[22] C. McHorney,et al. Understanding Diabetes Medications From the Perspective of Patients With Type 2 Diabetes , 2006, The Diabetes educator.